The BCL2L13 Knockout HAP1 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population in which the BCL2L13 gene has been disrupted. This human (Homo sapiens) near-haploid HAP1 cell model provides a heterogeneous pool of edited cells with loss-of-function mutations in the target gene, enabling robust functional genomics studies of BCL2L13 in a near-haploid background.
HAP1 cells are a suspension-adapted, near-haploid chronic myeloid leukemia (CML) cell line originally derived from KBM-7 cells. Possessing a predominantly haploid karyotype except for a disomic region on chromosome 15, HAP1 cells serve as a powerful platform for genetic screening and knockout-based phenotypic analyses. Their diploid-free genomic architecture minimizes genetic redundancy and facilitates unambiguous genotype-phenotype correlations, making them a preferred host for CRISPR-based knockout applications in drug discovery and basic research.
BCL2L13 (Bcl-rambo) encodes a mitochondrial outer membrane protein that plays a critical role in modulating mitochondrial dynamics, apoptosis, and mitophagy. BCL2L13 promotes mitochondrial fragmentation via direct interaction with DRP1 and has been implicated in both pro-apoptotic and pro-survival signaling depending on cellular context. It functions within the intrinsic apoptotic pathway, where it can sensitize mitochondria to cytochrome c release upon apoptotic stimuli. Upstream, BCL2L13 expression is regulated by TP53 in response to DNA damage and oxidative stress, and its activity intersects with BH3-only proteins. Key downstream events include DRP1-mediated fission, BNIP3 engagement, caspase activation, and cytochrome c release. BCL2L13 also interacts with mitophagy machinery components such as MUL1, ATG12, and LC3, positioning it at the interface of mitochondrial quality control and cell death decisions.
In the HAP1 cell context, BCL2L13 disruption permits detailed investigation of its role in mitochondrial remodeling and apoptotic sensitivity within a leukemia-derived background. The near-haploid nature enhances the detection of subtle phenotypes often masked in polyploid cells, and the polyclonal format captures a range of allelic disruptions, mimicking a population-level knockout effect. This model is particularly relevant for studying how BCL2L13-dependent mitochondrial regulation influences CML cell viability, drug response, and clonal fitness, providing insights into apoptosis evasion mechanisms in cancer.
Researchers can employ these polyclonal knockout cells in a variety of experimental workflows. Western blotting and immunofluorescence (e.g., MitoTracker staining) enable assessment of BCL2L13 protein loss and mitochondrial morphology changes. Flow cytometry-based apoptosis assays (Annexin V/PI) reveal alterations in cell death sensitivity, while mitophagy flux assays and co-immunoprecipitation with DRP1 elucidate functional interactions. The cells are also suited for high-throughput chemical screens targeting BCL2 family members or mitochondrial regulators, as well as CRISPR-based genetic interaction mapping. For more information or to discuss custom applications, please contact Ascent Research.
